IN8BIO, INC.
IN8BIO, INC. (INAB): 8 pipeline candidates · ~14 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.5 months
D/E 0.15 · 98% dilution
Lead: Phase 1/Phase 2
8 candidates
N/A
N/A
A transparent, data-derived signal for IN8BIO, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.4M
Cash
$22.2M
Quarterly Burn
$4.9M
Runway
13.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| allogeneic genetically modified gamma-delta t cells | Phase 1/Phase 2 |
| autologous genetically modified gamma-delta t cells | Phase 1/Phase 2 |
| inb-100 | Phase 1 |
| inb-200 | Phase 1 |
| inb-300 | Preclinical |
| inb-400 | Phase 2 |
| inb-600 | Preclinical |
| inb-619 | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$4.6M
| Holder | Shares | Value |
|---|---|---|
| alyeska investment group, l.p. | 944,319 | $1.4M |
| franklin resources inc | 914,531 | $1.4M |
| 683 capital management, llc | 724,637 | $1.1M |
| bios capital management, lp | 167,805 | $248K |
| vanguard capital management llc | 88,865 | $132K |
| geode capital management, llc | 86,239 | $128K |
| vanguard fiduciary trust co | 43,570 | $65K |
| captrust financial advisors | 33,295 | $49K |
| oppenheimer & co inc | 24,033 | $36K |
| texas capital bank wealth management services inc | 23,750 | $35K |
Showing top 10 of 18 institutional holders of IN8BIO, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IN8BIO, INC.'s pipeline?
IN8BIO, INC. (INAB) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IN8BIO, INC.'s lead drug candidate?
IN8BIO, INC.'s most advanced tracked candidate is allogeneic genetically modified gamma-delta t cells (Phase 1/Phase 2) for Glioblastoma.
What is IN8BIO, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IN8BIO, INC. has approximately 13.5 months of cash runway.
What is IN8BIO, INC.'s market capitalization?
IN8BIO, INC.'s market capitalization is approximately $13.4M.
Who is the CEO of IN8BIO, INC.?
Mr. Tai-Wei Ho is the chief executive officer of IN8BIO, INC. (INAB).
Get the full picture on IN8BIO, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.